Japan’s Aska To Revamp Production Operations In Productivity Move
This article was originally published in PharmAsia News
Aska Pharmaceutical says it plans to begin building a new $9.4 million production facility in April as part of a major expansion of its manufacturing operations. The new facility, in the Fukushima Prefecture, is expected to be ready to produce capsule drugs in two years, when Aska plans to close its Tokyo factory. As part of the overhaul, intended to allow greater productivity at lower costs, Aska also plans to form a joint venture with Akiyama Jozai to produce a line of hormone drugs. Hormone drugs and contraceptives account for nearly a third of Aska's sales. (Click here for more - a subscription may be required
You may also be interested in...
The European Commission has unexpectedly concluded that CBD should not be considered as drug opening up the path to regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.